AkesoBio, a Zhongshan novel drug discovery and development biopharma, filed for a $300 million Hong Kong IPO to develop its portfolio of novel mono- and bi-specific antibodies. The company has built a portfolio of 18 mAbs that are in either CMC or clinical stages of development for oncology, inflammation, autoimmune and cardiovascular diseases. In general, Akeso develops bispecific antibodies using a PD-1 antibody as a backbone. Late last year, Akeso Biopharma closed a $150 million Series D round of financing led by Loyal Valley Capital and Sino Biopharm.
Source: China Biotoday
